Indian pharmaceutical companies are set for a steady September quarter. Growth in the US generics market and domestic sales will drive performance. Companies like Apollo Hospitals, Lupin, and Aurobindo are expected to show strong results. Despite some cost pressures, the sector anticipates positive medium-term prospects. New product launches and expanding facilities will support earnings.
IPO Calendar: Issues worth Rs 3,300 crore lined up this week; Mahanadi Coalfields set for listing
The primary market is set for a busy week, with three IPOs expected to raise an estimated Rs 3,300 crore. Integris Medtech and Foodlink F&B